XML 30 R19.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value of Financial Instruments
3 Months Ended
Mar. 31, 2023
Fair Value Disclosures [Abstract]  
Fair Value of Financial Instruments Fair Value of Financial Instruments
The carrying amount of certain of the Company’s financial instruments, including cash and cash equivalents, net accounts receivable, note receivable, accounts payable and other accrued liabilities approximate fair value due to their short-term nature.
The Company measures the value of its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment. During the year ended December 31, 2021, Reneo completed its initial public offering. As a result, the fair value of the Company’s investment in Reneo’s common stock now has a readily determinable market value and is no longer eligible for the practical expedient for investments without readily determinable fair market values.
Assets and Liabilities Measured at Fair Value on a Recurring Basis
The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments. The Company determined that the promissory note receivable was level 2 and the fair value measurement was based on the market yield curves. The following table summarizes the conclusions reached regarding fair value measurements as of March 31, 2023 and December 31, 2022 (in thousands):
Balance at March 31, 2023Quoted Prices in Active
Markets for Identical Assets
(Level 1)
Significant Other Observable
Inputs
(Level 2)
Significant Unobservable Inputs
(Level 3)
Assets:
Equity securities with readily determinable fair value$3,447 $3,447 $— $— 
Total$3,447 $3,447 $— $— 
Liabilities:
Warrant liability, related party (1)
$922 $— $— $922 
Total$922 $— $— $922 
Balance at December 31, 2022Quoted Prices in Active
Markets for Identical Assets
(Level 1)
Significant Other Observable
Inputs
(Level 2)
Significant Unobservable Inputs
(Level 3)
Assets:
Equity securities with readily determinable fair value$1,343 $1,343 $— $— 
Total$1,343 $1,343 $— $— 
Liabilities:
Warrant liability, related party (1)
$684 $— $— $684 
Total$684 $— $— $684 
_____________________________
(1)Fair value determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation.
Changes in Level 3 instruments for the three months ended March 31,
Balance at January 1Net Change in
fair value included in
earnings
Purchases /
Issuance
Sales /
Repurchases
Balance at March 31,
2023
Warrant liability, related party$684 $238 $— $— $922 
Total$684 $238 $— $— $922 
2022
Warrant liability, related party$1,262 $(492)$— $— $770 
Total$1,262 $(492)$— $— $770 
There were no transfers into or out of level 3 instruments and/or between level 1 and level 2 instruments during the three months ended March 31, 2023. Gains and losses recognized due to the change in fair value of the warrant liability, related party are recognized as a component of other (expense) income, related party in the Company’s Condensed Consolidated Statements of Operations.
The fair value of the Letter Agreement Warrants was determined using the Black-Scholes option pricing model or option pricing models based on the Company’s current capitalization. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the Letter Agreement Warrants as of March 31, 2023 and December 31, 2022, were:
March 31, 2023December 31, 2022
RangeWeighted AverageRangeWeighted Average
Expected volatility
73.22% - 83.59%
81.39%
76.94% - 85.88%
82.17%
Risk-free interest rate
3.73% - 4.24%
3.84%
4.11% - 4.43%
4.19%
The fair value of the CinRx Warrants was determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the CinRx Warrants as of March 31, 2023, were:
Expected volatility 82.2 %
Expected life of options in years3.6
Risk-free interest rate3.7 %
Expected dividend yield— %
The weighted average expected volatility and risk-free interest rate was based on the relative fair values of the warrants.
Changes in the unobservable inputs noted above would impact the amount of the liability for the Letter Agreement Warrants and CinRx Warrants. Increases (decreases) in the estimates of the Company’s annual volatility would increase (decrease) the liability and an increase (decrease) in the annual risk-free rate would increase (decrease) the liability.